Meta-Analysis Compares Tx for Inducing Remission in Crohn's

This article originally appeared here.
Share this content:
Meta-Analysis Compares Tx for Inducing Remission in Crohn's
Meta-Analysis Compares Tx for Inducing Remission in Crohn's

(HealthDay News) -- For adult patients with Crohn's disease, adalimumab and infliximab + azathioprine are most effective for induction and maintenance of remission, according to a meta-analysis published in the February issue of Gastroenterology.

Glen S. Hazlewood, M.D., from the University of Calgary in Canada, and colleagues conducted a systematic review to compare therapies for induction and maintenance of remission in patients with Crohn's disease. Data were included from 39 randomized controlled trials that compared methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab, vedolizumab, or combined therapy with placebo or an active agent in adults with Crohn's disease.

The researchers found that for induction of remission, infliximab, infliximab + azathioprine, adalimumab, and vedolizumab were superior to placebo. In pairwise comparisons, infliximab + azathioprine and adalimumab were superior to certolizumab for induction of remission (odds ratios, 3.1 and 2.1, respectively). For maintaining remission, all treatments were superior to placebo except for the combination infliximab and methotrexate. For maintenance of remission, adalimumab, infliximab, and infliximab + azathioprine were superior to azathioprine/6-mercaptopurine (odds ratios, 2.9, 1.6, and 3.0, respectively). Adalimumab and infliximab + azathioprine were superior to certolizumab (odds ratios, 2.5 and 2.6, respectively); adalimumab was superior to vedolizumab (odds ratio, 2.4).

"Based on a network meta-analysis, adalimumab and infliximab + azathioprine are the most effective therapies for induction and maintenance of remission of Crohn's disease," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »